Davida Kruger, APRN
Nurse Practitioner · Detroit, MINPI 1497897961
Payments from drug & device makers
Across 1,133 payments — averaging $1558.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$415K
- Abbott$316K
- Sequel Med Tech, LLC$250K
- Novo Nordisk$210K
- Dexcom, Inc.$200K
- Insulet Corporation$184K
- plus $191K from 11 others
What the payments were for
- Consulting fees$167,89723%
- Speaking & faculty fees$478,57265%
- Travel & lodging$76,13510%
- Food & beverage$15,8942%
- Education$1600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 5 | $415,081 |
| Abbott | 162 | $316,140 |
| Sequel Med Tech, LLC | 260 | $250,095 |
| Novo Nordisk | 170 | $209,877 |
| Dexcom, Inc. | 137 | $199,759 |
| Insulet Corporation | 113 | $183,674 |
| Lilly USA, LLC | 203 | $97,978 |
| Cequr Corporation | 7 | $23,351 |
| Sanofi-aventis U.S. LLC | 16 | $21,875 |
| Corcept Therapeutics | 17 | $10,636 |
| Embecta Corp. | 4 | $9,830 |
| Eli Lilly | 8 | $9,766 |
| Mannkind Corporation | 6 | $6,362 |
| Medtronic | 16 | $5,742 |
| Xeris Pharmaceuticals, Inc. | 4 | $4,187 |
| Ascensia Diabetes Care US Inc. | 4 | $1,409 |
| AstraZeneca | 1 | $127 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$95,119
- Ozempic$94,508
- DEXCOM G6 TRANSMITTER$81,727
- MOUNJARO$75,635
- RYBELSUS$63,840
- Omnipod$60,139
- FREESTYLE LIBRE 3$58,489
- DEXCOM STELO GLUCOSE BIOSENSOR$24,955
- CeQur Simplicity$23,351
- FreeStyle Libre$14,113
- FreeStyle Libre Pro$11,888
- TOUJEO$11,642
- TRULICITY$11,050
- Korlym$10,320
- AFREZZA$6,232
- GVOKE PFS$4,158
- Tresiba$4,125
- TWIIST$4,065
- TZIELD$3,551
- t:slim X2 Insulin Pump with Control-IQ$2,633
How this compares
$1,765,889 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $168,883 |
| JardianceEmpagliflozin | 47 | $67,918 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 37 | $53,855 |
| TrulicityDulaglutide | 18 | $32,963 |
| NovologInsulin Aspart | 75 | $29,690 |
| MounjaroTirzepatide | 24 | $25,803 |
| Novolog FlexpenInsulin Aspart | 40 | $14,736 |
| HumalogInsulin Lispro | 27 | $12,976 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $12,840 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $10,941 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $10,850 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $10,434 |
| Gvoke Hypopen 2-PackGlucagon | 13 | $10,136 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $8,873 |
| Admelog SolostarInsulin Lispro | 13 | $5,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $209,877 | $198,573164 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $97,978 | $71,74269 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Detroit
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Rosanne OsoskiDetroit$25K
- Amy BlakeDetroit$17K
- Tanya McCauleyDetroit$15K
- Linda ManninoDetroit$12K
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Abubakir BabanDearborn$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.